Journal: Biomolecules

Article Title: Nucleoside Analogs in ADAR Guide Strands Enable Editing at 5′-G A Sites

doi: 10.3390/biom14101229

Figure Lengend Snippet: Dual luciferase assay measuring cellular editing with MECP2 R255X reporter plasmid and overexpressed ADARs in HEK293 cells. ( A ) Guide oligonucleotide design for directed editing of the MECP2 R255X in cellulo. Target A is highlighted in red. All nucleotides bear 2′-O-methyl modifications and contain phosphodiester linkages with the following exceptions: * indicates phosphorothioate modification, bold indicates 2′-deoxyribonucleotides. ( B ) Schematic of reporter plasmid construct encoding MECP2 R255X mutation sequence followed by sequence encoding nanoluciferase and an independent promoter for firefly luciferase expression. ( C ) Relative nLuc/fLuc luminescence signals observed for guide oligonucleotides with varying identity of nucleoside analogs at −1 position and a 3 nM, 10 nM, and 30 nM concentration of guide with overexpressed ADAR2. Cells were lysed and luminesced at 48 h. A two-tailed Welch’s t test was conducted, where ** p < 0.01, *** p < 0.001.

Article Snippet: Molecular weights for editing oligonucleotide (EON)-bearing phosphorothioate backbone modifications were obtained from Novatia Inc. (Newton, PA, USA) using ESI-MS. Sequences and mass spectrometry data for all oligonucleotides are found in .

Techniques: Luciferase, Plasmid Preparation, Modification, Construct, Mutagenesis, Sequencing, Expressing, Concentration Assay, Two Tailed Test

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: MicroRNA in cancer therapy: breakthroughs and challenges in early clinical applications

doi: 10.1186/s13046-025-03391-x

Figure Lengend Snippet: Most relevant recent clinical trial in the treatment of solid and hematological malignancies

Article Snippet: miR-155 , Cobomarsen , Antisense oligonucleotide (ASO) , PS backbone modification , Cutaneous T-cell lymphoma (Mycosis Fungoides Subtype), DLBCL , Phase I/ II , NCT02580552Completed NCT03713320Terminated , Intravenous , miRagen Therapeutics, Inc , .

Techniques: Modification